Tamtam Try Tamtam free
DBV Technologies logo

DBV Technologies account plan

Food allergy skin patch

At a glance

DBV Technologies is a French late-stage biopharma developing the Viaskin Peanut patch, with a BLA filed at the FDA in September 2026.

DBV Technologies is a late-stage specialty biopharmaceutical company headquartered in Châtillon, France, with North American operations in Warren, New Jersey. It develops one platform, Viaskin, a skin patch that delivers allergen through intact skin (epicutaneous immunotherapy, EPIT), aimed first at children with peanut allergy. It reports one operating segment and had no revenue in 2025; its FY2025 net loss was $146.9 million and it had 125 full-time employees at December 31, 2025. Its ordinary shares are listed on Euronext Paris and its ADSs on the Nasdaq Capital Market. Clinical trials are run by CROs and patches are made by contract manufacturers.

Business units

Strategic priorities

US approval of Viaskin Peanut for children 4-7
The BLA was submitted on September 30, 2026 after FDA feedback on the organisation and formatting of CMC and biostatistical data moved it from the second to the third quarter of 2026; the FDA did not request additional data. DBV requested Priority Review, which would take six months once the file is accepted.
Toddler (1-3) BLA
A BLA under an Accelerated Approval pathway is planned for the second half of 2026, conditional on COMFORT Toddlers, whose recruitment closed in the second quarter of 2026.
Building a US commercial organisation
DBV is investing in market access, patient services, brand readiness, field force planning and launch operations; Kevin Trapp was appointed Chief Commercial Officer on November 3, 2025. The 10-K sizes the opportunity at about 670,000 US children aged 1 to 7 with peanut allergy and about 4,500 US allergists.
European resubmission
EMA scientific advice indicated that EPITOPE plus a positive VITESSE, with a new toddler safety study, could support an MAA for ages 1-7; DBV intends to resubmit once that data set is available.
Extending the platform to infants
The Phase 2 THRIVE study in infants aged 6 through 12 months screened its first participant on June 2, 2026.

Latest results

DBV generated no revenue in the first half of 2026. Its H1 2026 net loss was $98.0 million (H1 2025: $69.0 million), with R&D up 17% to $64.6 million, sales and marketing at $10.4 million (H1 2025: $0.7 million) and G&A up 78% to $25.1 million as it builds US commercial infrastructure. Average headcount rose to 170 in H1 2026 from 109 a year earlier. Cash and cash equivalents were $174.9 million at June 30, 2026, and after the BLA delay management estimates runway into the third quarter of 2027, including cost-containment measures.

Investments and deals

2025 PIPE and ATM financing
Initial PIPE gross proceeds of $125.5 million in April 2025, followed by $195 million from full warrant exercise after VITESSE; $65 million raised through the ATM programme in the fourth quarter of 2025. The final $94 million of warrant proceeds arrived in January 2026.
Commercial patch capacity at Fareva Amboise
A June 25, 2026 letter of intent covers readiness work, equipment upgrades and workforce expansion for commercial patch production: a planned investment of about $7.5 million, of which up to $5.2 million is to be supported by DBV, contingent on FDA approval.
Peanut Source Material line at Fareva La Vallée
A dedicated production line with technology transfer from Sanofi, under a manufacturing and supply agreement effective March 17, 2026, exclusive to DBV for eight years.
US distribution services
A June 5, 2026 letter of intent with ICS for US commercialisation support and distribution services if the product is approved.

Challenges and risks

Single-source manufacturing under FDA scrutiny
The FDA has issued warning letters to Fareva Amboise, DBV's sole patch manufacturer, citing cGMP deficiencies; DBV has no readily available alternative source, and Sanofi is the only API manufacturer.
Cash burn before any revenue
Operating cash use was $101.7 million in H1 2026, the accumulated deficit reached $1,553 million at the end of 2025, and no ATM sales are possible until a new Form S-3 is effective.
Regulatory history
A BLA was withdrawn in 2018, a Complete Response Letter asking for CMC data followed in August 2020, and the EU MAA was withdrawn in 2021.
Building commercial capabilities from scratch
DBV must build sales, marketing, distribution and market access, and has not finalised a price; Xolair is priced from around $10,000 into the $30,000s in this age range.

What leadership says

“2026 is and will continue to be a pivotal year for DBV. We are working aggressively to transform the company into a commercial organization in anticipation of the potential approval of the Viaskin Peanut patch for children aged four through seven by the FDA.”

Daniel Tassé, Chief Executive Officer · Q2 2026 results conference call, July 16, 2026

“The submission of our BLA brings VIASKIN Peanut Patch, a non-invasive, practical treatment option, one step closer to being available for children ages 4 through 7 living with peanut allergy, and marks a significant milestone in DBV's transformation into a commercial organization”

Daniel Tassé, Chief Executive Officer · BLA submission press release, September 30, 2026

“It's certainly a tremendous amount of work to move from the clinical to commercial stage.”

Daniel Tassé, Chief Executive Officer · Q2 2026 results conference call, July 16, 2026

Where a supplier can help

Launch operations and market access
Tied to the US commercial build-out: DBV is investing in market access, patient services, brand readiness and field force planning ahead of a potential approval, which opens room for launch, payer and patient-services partners.
Quality and cGMP remediation support
Tied to the Fareva warning letters: DBV is working with its sole patch manufacturer on remediation, where quality, compliance and supply-chain expertise could reduce approval risk.
Regulatory submission tooling
Tied to the BLA delay: FDA feedback concerned the organisation, mapping and formatting of CMC and biostatistical data sets, and the toddler BLA is still to come, so regulatory publishing and data-management support is relevant.
Cost-conscious back-office scaling
Tied to cash burn and cost containment: G&A and headcount are rising while runway is set into the third quarter of 2027, so offers that scale HR, IT, finance or compliance without fixed cost fit the budget discipline DBV describes.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like DBV Technologies?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about DBV Technologies

What does DBV Technologies do?

DBV develops Viaskin, a skin patch that delivers allergen through intact skin to treat food allergy. Its lead product, the Viaskin Peanut patch, targets children with peanut allergy; no DBV product is yet authorised for sale.

Does DBV Technologies have revenue?

No. DBV had no revenue in 2025 or H1 2026; it reported a FY2025 net loss of $146.9 million and an H1 2026 net loss of $98.0 million, and had $174.9 million of cash at June 30, 2026.

How many employees does DBV Technologies have?

DBV had 125 full-time employees at December 31, 2025, and an average headcount of 170 in H1 2026.

Who leads DBV Technologies?

Daniel Tassé is Chief Executive Officer, Virginie Boucinha is Chief Financial Officer and Kevin Trapp is Chief Commercial Officer.

What is DBV's strategy?

DBV is turning itself into a commercial company: it filed a BLA for Viaskin Peanut in children 4-7 in September 2026, plans a toddler BLA, and is building US launch capabilities.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)